

Capital markets event Meet AZN management: ASCO 2020

Pascal Soriot, Dave Fredrickson, José Baselga

IR moderator: Thomas Kudsk Larsen

1 June 2020 Webinar is being recorded



Forward-looking statements disclaimer

2

In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter 'the Group') provides the following cautionary statement: this document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or other financial or other measures. Although the Group believes its expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this document and the Group undertakes no obligation to update these forward-looking statements. The Group identifies the forward-looking statements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond the Group's control, include, among other things: the risk of failure or delay in delivery of pipeline or launch of new medicines; the risk of failure to meet regulatory or ethical requirements for medicine development or approval; the risk of failure to obtain, defend and enforce effective intellectual property (IP) protection and IP challenges by third parties; the impact of competitive pressures including expiry or loss of IP rights, and generic competition; the impact of price controls and reductions; the impact of economic, regulatory and political pressures; the impact of uncertainty and volatility in relation to the UK's exit from the EU; the risk of failures or delays in the guality or execution of the Group's commercial strategies; the risk of failure to maintain supply of compliant, guality medicines; the risk of illegal trade in the Group's medicines; the impact of reliance on third-party goods and services; the risk of failure in information technology, data protection or cybercrime; the risk of failure of critical processes; any expected gains from productivity initiatives are uncertain; the risk of failure to attract, develop, engage and retain a diverse, talented and capable workforce; the risk of failure to adhere to applicable laws, rules and regulations; the risk of the safety and efficacy of marketed medicines being questioned; the risk of adverse outcome of litigation and/or governmental investigations; the risk of failure to adhere to increasingly stringent anti-bribery and anti-corruption legislation; the risk of failure to achieve strategic plans or meet targets or expectations; the risk of failure in financial control or the occurrence of fraud; the risk of unexpected deterioration in the Group's financial position; and the impact that the COVID-19 global pandemic may have or continue to have on these risks, on the Group's ability to continue to mitigate these risks, and on the Group's operations, financial results or financial condition. Nothing in this document, or any related presentation/webcast, should be construed as a profit forecast.

Agenda


Introduction and overview

Oncology strategy and growth

ASCO 2020 highlights

- Tagrisso adjuvant lung cancer (ADAURA trial)
- Imfinzi small cell lung cancer (CASPIAN trial)
- Enhertu gastric, lung and colorectal cancers (DESTINY trials)

Virtual breakout sessions





Meet AZN management: ASCO 2020 Four Q&A-focused, virtual breakout sessions

Opening session

16:00-16:25 BST

Pascal Soriot, Dave Fredrickson, José Baselga

https://astrazeneca.zoom.us/webinar/register/WN_hEt-K5tqRGOxefPVfBtTdg Webinar ID: 957 3417 3925 | IR moderator: thomas.larsen@astrazeneca.com

Enhertu and

breast cancer

Session 1: 16:35 BST Session 2: 17:15 BST

José Baselga, Mika Sovak, Jon Wildin

https://astrazeneca.zoom.us/webinar/register/WN_Mux3EqBhTmeTmtJ-UuhVYA

Webinar ID: 995 5382 4818 IR moderator: tom.waldron@astrazeneca.com

Lynparza

Session 1: 16:35 BST Session 2: 17:15 BST

Susan Galbraith, Greg Rossi

https://astrazeneca.zoom.us/webinar/re gister/WN_gvp6EHQ6TW2i9LikUbrx3Q

> Webinar ID: 989 7940 1118 IR moderator: nick.stone@astrazeneca.com

Calquence and haematology

Session 1: 16:35 BST Session 2: 17:15 BST

Michelle Werner, Andrew Mortlock

https://astrazeneca.zoom.us/webinar/re gister/WN_Tx4eYAyFSxi4nQ2x8iMkNA

Webinar ID: 933 8283 0734 IR moderator: henry.wheeler@astrazeneca.com

If you cannot connect using Zoom Webinar on a computer or device, please use the following phone details: +441314601196 | +46844682488 | +16699006833, including the appropriate Webinar ID

Event closes c. 17:45 BST

Tagrisso and immuno-oncology

Session 1: 16:35 BST Session 2: 17:15 BST

Dave Fredrickson, Cristian Massacesi


https://astrazeneca.zoom.us/webinar/re gister/WN_-ScpPmA9TRST-5NET3fEig

> Webinar ID: 936 3943 3037 IR moderator: craig.marks@astrazeneca.com

4

ASCO 2020 Increasing presence

103 presented abstracts 26% increase over 2019



Source: ASCO 2020 accepted abstracts. A total of 132 abstracts were accepted of which 29 abstracts were selected for publication only.

Data highlights

- **Tagrisso** Phase III ADAURA - adjuvant lung cancer (plenary, late-breaking abstract)
- *Imfinzi* Phase III CASPIAN - extensivestage small cell lung cancer
- Enhertu

•

•

Phase II trials in gastric, lung and colorectal cancers and update in breast cancer



ASCO 2020: data from across the portfolio 'What's next' pipeline featured in many abstracts

What's next

Phase I/II new medicines, selected

adavosertibData atmonalizumabData a(WEE11 inhibitor)ASCO (NKG2a ⁶ mAb ⁷)ASCO solid tumourshead & neck, colorectal cancers
ceralasertibData at (ATR2 inhibitor)Oleclumab (CD738 mAb) lung, pancreatic cancers
AZD9833Data at (SERD3, oral)ASCO AZD4635Data at (A2AR9 inhibitor)breast cancersolid tumours
AZD5991MEDI5752(MCL14 inhibitor)(PD-110 / CTLA-411)blood cancerssolid tumours
AZD2811AZD4573(Aurora B inhibitor)(CDK912 inhibitor)solid tumours, blood cancersblood cancers
AZD0466MEDI2228(Bcl-2 ⁵ /xL)(BCMA ¹³ ADC ¹⁴)blood cancersblood cancers

What's now

Phase III new medicines



Phase III lifecycle management, major



1. Tyrosine kinase WEE1 2. Ataxia telangiectasia and rad3-related kinase 3. Selective oestrogen receptor degrader 4. Induced myeloid leukaemia cell differentiation protein 5. B-cell lymphoma 2 6. Inhibitory cell surface receptor covalently bound to CD94 7. Monoclonal antibody 8. 5'-nucleotidase 9. Adenosine A2A receptor 10. Programmed cell death protein 1 11. Cytotoxic T-lymphocyte-associated protein 4 12. Cyclin-dependent kinase 9 13. B-cell maturation antigen 14. Antibody-drug conjugate 15. Phase II.

6

Agenda


Introduction and overview

Oncology strategy and growth

ASCO 2020 highlights


- Tagrisso adjuvant lung cancer (ADAURA trial)
- Imfinzi small cell lung cancer (CASPIAN trial)
- Enhertu gastric, lung and colorectal cancers (DESTINY trials)

Virtual breakout sessions






Oncology: a leading, diversified portfolio



1. Non-small cell lung cancer 2. Epidermal growth factor receptor mutation 3. 1st line 4. Substitution of threonine (T) with methionine (M) at position 790 of exon 20 mutation 5. 2nd line 6. Small cell lung cancer 7. Exact patient population varies by indications 8. 3rd line 9. Human epidermal growth factor receptor 2 positive.

8

Oncology: strong growth across medicines and geographies



US Europe Established Rest of World (RoW) Emerging markets Absolute product sales at actual exchange rates. 1. Metastatic breast cancer.

9

Agenda

Introduction and overview


Oncology strategy and growth

ASCO 2020 highlights

- Tagrisso adjuvant lung cancer (ADAURA trial)


- Imfinzi small cell lung cancer (CASPIAN trial)
- Enhertu gastric, lung and colorectal cancers (DESTINY trials)

Virtual breakout sessions





ADAURA Phase III double-blind study design



Endpoints

PRESENTED AT:

- Primary: DFS, by investigator assessment, in stage II/IIIA patients; designed for superiority under the assumed DFS HR of 0.70
- Secondary: DFS in the overall population¹, DFS at 2, 3, 4, and 5 years, OS, safety, health-related quality of life

Following IDMC recommendation, the study was unblinded early due to efficacy; here we report an unplanned interim analysis

· At the time of unblinding the study had completed enrollment and all patients were followed up for at least 1 year

11

2020 ASCO #ASCO20 ANNUAL MEETING #ASCO20

PRESENTED BY ROY S. Herbst

NC102511105; ADAURA data cut-off: January 17, 2020. "AJCC 7th editor; "Prior, post, or planned radiothenary was not allowed. Cantally confirmed in tasue; "Patients received a CT scan after resoction and with 728 days prior to treatment, "Stage 18/1/ 1/14. CT, computed temporary, Ex195et, each 19 deletion; IDMC, independent Data Monitoring Committee; WHO, World Health Organization.

2020ASCO


ANNUAL MEETING

#ASCO20

Eisles are the property of the author periods and required for reside.

All causality adverse events (≥10% of patients)

Median duration of exposure: osimertinib: 22.3 months (range 0 to 43), placebo: 18.4 months (range 0 to 48)



PRESENTED BY ROY 5. Herbst

One patient in the placebo arm reported a Grade 5 pulmonary embolism

URTL upper respiratory tract infection

*Grade 1, n=5; Grade 2, n=4; *ceimerlinib: Grade 1, n=14; Grade 2, n=5; Grade 3, n=3; placebo: Grade 1, n=3; Grade 3, n=1

12

PRESENTED AT:

1.0 90% 0.9 Median DFS, months (95% CI) 80% - Osimertinib 0.8 NR (38.8, NC) - Placebo 20.4 (16.6, 24.5) 0.7 HR (95% CI) 0.17 (0.12, 0.23); p<0.0001 DFS probability 0.6 61% Maturity 33%: 0.5 osimertinib 11%, placebo 55% 0.4 44% 0.3 28% 0.2 0.1 0.0 0 12 24 30 42 6 18 36 48 Time from randomization (months) No, at risk 219 189 137 96 17 Osimertinib 233 51 2 0 51 27 237 190 128 82 9 1 0 Placebo

Primary endpoint: DFS in patients with stage II/IIIA disease

13


PRESENTED AT:

2020ASCO #ASCO20 Eisles are the property of the author periodication required for reside. ANNUAL MEETING

PRESENTED BY ROY S. Herbst

ADAURA data cut-off, January Median follow up: osimertinib 22 1, placebo: 15.0 months DFS by investigator assessment. Tick marks to land

Secondary endpoint: DFS in the overall population (stage IB/II/IIIA)



14

2020 ASCO

PRESENTED AT:

ASCO20

PRESENTED BY ROY 5. Herbst

ADAJRA data cut-off, January 17, 2020. Median follow-up: ceimertinib 22.1, piscebe: 15.5 months. DFS by investigator assessment, Tick marks indicate censored data.

DFS across subgroups in the overall population

Subgroup			HR	95% CI
Overall (N=682)	Stratified log-rank		0.21	0.16, 0.28
	Unadjusted Cox PH		0.20	0.14, 0.29
Sex	Male (n=204)	,	0.21	0.11, 0.36
	Female (n=478)		0.20	0.12, 0.30
Age	<65 (n=380)	·	0.18	0.10, 0.28
	≥65 (n=302)		0.24	0.14, 0.38
Smoking status	Smoker (n=194)		0.14	0.06, 0.27
	Non-smoker (n=488)		0.23	0.15, 0.34
Race	Asian (n=434)		0.22	0.14, 0.33
	Non-Asian (n=248)		• • 0.17	0.08, 0.31
Stage	Stage IB (n=212)		0.50	0.25, 0.96
	Stage II (n=236)		• 0.17	0.08, 0.31
	Stage IIIA (n=234)	·•	0.12	0.07, 0.20
EGFRm	Ex19del (n=378)		0.12	0.07, 0.20
	L858R (n=304)		⊢ ● 1 0.35	0.21, 0.55
Adjuvant chemotherapy	Yes (n=378)		0.18	0.11, 0.29
	^{py} No (n=304)		0.23	0.13, 0.38
		0.01 0.1 HR for disease-free	ee survival (95% CI)	
			Favors osimertinib Favors placebo	


15

PRESENTED AT: 2020ASCO

#ASCO20 History are the property of the author, periodialise required for record. ANNUAL MEETING

PRESENTED BY ROY S. Herbst

Early snapshot: overall survival in patients with stage II/IIIA disease



Conclusions

- Adjuvant osimertinib is the first targeted agent in a global trial to show a statistically significant and clinically meaningful improvement in DFS in patients with stage IB / II / IIIA EGFRm NSCLC
 - Overall, there was a 79% reduction in the risk of disease recurrence or death with osimertinib (DFS HR 0.21 [95% CI 0.16, 0.28]; p<0.0001)
 - Osimertinib vs placebo DFS rates at 2 years were 89% vs 53%, respectively
- A consistent improvement in DFS was seen regardless of whether patients received prior adjuvant chemotherapy
- The safety profile was consistent with the established safety profile of osimertinib, with mild EGFR-TKI class effects reported; median duration of exposure to osimertinib was 22 months

Adjuvant osimertinib will provide a highly effective, practice changing treatment for patients with stage IB / II / IIIA EGFRm NSCLC after complete tumor resection



PRESENTED AT:

2020 ASCO #ASCO20 ANNUAL MEETING Hard or the preserve of the action

PRESENTED IN ROY S. Herbst

Agenda


Introduction and overview

Oncology strategy and growth

ASCO 2020 highlights

- Tagrisso adjuvant lung cancer (ADAURA trial)
- Imfinzi small cell lung cancer (CASPIAN trial)
- Enhertu gastric, lung and colorectal cancers (DESTINY trials)


Virtual breakout sessions





Imfinzi CASPIAN - 1

Updated Overall Survival: D+EP vs EP



19

PRESENTED AT:

2020ASCO #ASCO20 Eldes are the property of the outline ANNUAL MEETING

PRESENTED BY: LUIS Paz-Ares

Imfinzi CASPIAN - 2

2020ASCO

#ASCO20

to ove like property of the author

Conclusions

- First-line durvalumab + EP continued to demonstrate sustained improvement in OS compared with a robust control arm that allowed up to 6 cycles of EP and the use of PCI
 - OS HR 0.75 (95% CI 0.62–0.91; nominal p=0.0032)
 - Sustained separation of OS curves with 22.2% vs 14.4% of patients alive at 24 months
 - Benefit was observed across all pre-specified subgroups and key secondary efficacy outcomes
- Addition of tremelimumab to durvalumab + EP did not significantly improve outcomes in CASPIAN
- · Safety findings in all arms remained consistent with the known safety profiles of all agents
- These results further support durvalumab + EP as a new standard-of-care treatment for first-line ES-SCLC offering the flexibility of platinum choice

PRESENTED BY: LUIS Paz-Ares

PRESENTED AT:

Agenda


Introduction and overview

Oncology strategy and growth

ASCO 2020 highlights

- Tagrisso adjuvant lung cancer (ADAURA trial)
- Imfinzi small cell lung cancer (CASPIAN trial)
- Enhertu gastric, lung and colorectal cancers (DESTINY trials)

Virtual breakout sessions






Enhertu gastric cancer - 1

DESTINY-Gastric01 Primary Endpoint: ORR

	N24	
	T-DXd (n = 119)	PC (n = 56)
ORR by ICR	51.3% (n = 61)	14.3% (n = 8)
(CR + PR)	95% Cl, 41.9-60.5; P < .0001	95% Cl, 6.4-26.2
Confirmed ORR by ICR	42.9% (n = 51)	12.5% (n = 7)
(CR + PR)	95% Cl, 33.8-52.3	95% CI, 5.2-24.1
CR	8.4% (n = 10)	0
PR	34.5% (n = 41)	12.5% (n = 7)
SD	42.9% (n = 51)	50.0% (n = 28)
PD	11.8% (n = 14)	30.4% (n = 17)
Not evaluable	2.5% (n = 3)	7.1% (n = 4)
Confirmed DCR	85.7% (n = 102)	62.5% (n = 35)
(CR + PR + SD)	95% CI, 78.1-91.5	95% CI, 48.5-75.1
Median confirmed DOR	11.3 months	3.9 months
Wedian commed DOR	95% CI, 5.6-NE	95% CI, 3.0-4.9



Best Percentage Change from Baseline in Tumor Size

Includes data for the response evaluable set: all randomized patients who received ≥1 dose of study drug and had measurable tumors based on independent central review at baseline. Line at 20% indicates progressive disease; line at -30% indicates partial response. Includes patients who had both baseline and postbaseline target lesion assessments by independent central review in both treatment arms.



PRESENTED AT:


2020 ASCO ANNUAL MEETING

PRESENTED IM Dr Kohel Shitara, National Cancer Center Hospital East, Chiba, Japan; kshitara@east.ncc.go.jp

Enhertu gastric cancer - 2

DESTINY-Gastric01 **Overall and Progression-Free Survival**





23


PRESENTED AT:

2020ASCO #ASCO20 Eistes are the property of the author perioductor required for record. ANNUAL MEETING

PRESENTED IM Dr Kohel Shitara National Cancer Center Hospital East, Chiba, Japan; kshitara@east.ncc.go.jp

Enhertu gastric cancer - 3

DESTINY-Gastric01 Safety Summary



TEAEs associated with:	T-DXd (n = 125)	PC (n = 62)
Drug discontinuation	15.2%	6.5%
Dose reduction	32.0%	33.9%
Dose interruption	62.4%	37.1%

- There was 1 drug-related death due to pneumonia with T-DXd and none with PC
- 12 patients (9.6%) had T-DXd-related ILD/pneumonitis as determined by an independent adjudication committee
 - Median time to first onset, 84.5 days (range, 36-638 days)
 - Most were grade 1 or 2 (grade 1, n=3; grade 2, n=6; grade 3, n=2; grade 4, n=1; no grade 5 events)

24

PRESENTED AT:


2020 ASCO

G HASCO20

PRESENTED BY Dr Kohei Shitara, National Cancer Center Hospital East, Chiba, Japan; kshitara@east.ncc.go.jp

Enhertu lung cancer - 1

DESTINY-Lung01 HER2-Mutated NSCLC Best Change in Tumor Size



Based on independent central review. Baseline is last measurement taken before enrollment. Shown is best (minimum) percent change from baseline in the sum of diameters for all target lesions. * One patient was missing a baseline assessment and 2 additional patients were missing post-baseline assessments.

25 PRESENTED AT: 2020ASCO ANNUAL MEETING

#ASCO20


PRESENTED BY Prof Egbert F. Smit: Netherlands Cancer Institute: e.smit@nki.nl

Enhertu lung cancer - 2

DESTINY-Lung01 HER2-Mutated NSCLC



Treatment-Emergent Adverse Events in >15% of Patients



PRESENTED AT: 2020ASCO


26

G HASCO20 G Here are the preparity of the eacher G Here and the preparity of the eacher

PRESENTED BY Prof Egbert F. Smit; Netherlands Cancer Institute; e.smit@nki.nl

Enhertu colorectal cancer - 1








G #ASCO20

PRISONTED IM Prof Salvatore Siena; Università degli Studi di Milano, Milan, Italy, salvatore siena@unimi.it

27

Enhertu colorectal cancer - 2

Treatment-Emergent Adverse Events in >15% of Patients



⁴ Grade ≥3 neutrophil count decreased, 25.6%; no patients had febrile neutropenia.

PRESENTED AT: 2020 ASCO ANNUAL MEETING

#ASCO20 Divise are the present of the author permanent received for reads.

PRESENTED IN Prof Salvatore Siena; Università degli Studi di Milano, Milan, Italy; salvatore.siena@unimi.it

28

Agenda


Introduction and overview

Oncology strategy and growth

ASCO 2020 highlights

- Tagrisso adjuvant lung cancer (ADAURA trial)
- Imfinzi small cell lung cancer (CASPIAN trial)
- Enhertu gastric, lung and colorectal cancers (DESTINY trials)

Virtual breakout sessions





Meet AZN management: ASCO 2020 Four Q&A-focused, virtual breakout sessions

Opening session

16:00-16:25 BST

Pascal Soriot, Dave Fredrickson, José Baselga

https://astrazeneca.zoom.us/webinar/register/WN_hEt-K5tqRGOxefPVfBtTdg Webinar ID: 957 3417 3925 | IR moderator: thomas.larsen@astrazeneca.com

Enhertu and

breast cancer

Session 1: 16:35 BST Session 2: 17:15 BST

José Baselga, Mika Sovak, Jon Wildin

https://astrazeneca.zoom.us/webinar/re gister/WN_Mux3EqBhTmeTmtJ-UuhVYA

> Webinar ID: 995 5382 4818 IR moderator: tom.waldron@astrazeneca.com

Lynparza

Session 1: 16:35 BST Session 2: 17:15 BST

Susan Galbraith, Greg Rossi

https://astrazeneca.zoom.us/webinar/re gister/WN_gvp6EHQ6TW2i9LikUbrx3Q

> Webinar ID: 989 7940 1118 IR moderator: nick.stone@astrazeneca.com

Calquence and haematology

Session 1: 16:35 BST Session 2: 17:15 BST

Michelle Werner, Andrew Mortlock

https://astrazeneca.zoom.us/webinar/re gister/WN_Tx4eYAyFSxi4nQ2x8iMkNA

Webinar ID: 933 8283 0734 IR moderator: henry.wheeler@astrazeneca.com

If you cannot connect using Zoom Webinar on a computer or device, please use the following phone details: +441314601196 | +46844682488 | +16699006833, including the appropriate Webinar ID

Event closes c. 17:45 BST

Tagrisso and immuno-oncology

Session 1: 16:35 BST Session 2: 17:15 BST

Dave Fredrickson, Cristian Massacesi

https://astrazeneca.zoom.us/webinar/re gister/WN_-ScpPmA9TRST-5NET3fEig

> Webinar ID: 936 3943 3037 IR moderator: craig.marks@astrazeneca.com



Use of AstraZeneca conference call, webcast and presentation slides

The AstraZeneca webcast, conference call and presentation slides (together the 'AstraZeneca Materials') are for your personal, non-commercial use only. You may not copy, reproduce, republish, post, broadcast, transmit, make available to the public, sell or otherwise reuse or commercialise the AstraZeneca Materials in any way. You may not edit, alter, adapt or add to the AstraZeneca Materials in any way, nor combine the AstraZeneca Materials with any other material. You may not download or use the AstraZeneca Materials for the purpose of promoting, advertising, endorsing or implying any connection between you (or any third party) and us, our agents or employees, or any contributors to the AstraZeneca Materials. You may not use the AstraZeneca Materials in any way that could bring our name or that of any Affiliate into disrepute or otherwise cause any loss or damage to us or any Affiliate. AstraZeneca PLC, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA. Telephone + 44 20 3749 5000, www.astrazeneca.com

